nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—OPRK1—Amitriptyline—migraine	0.339	0.376	CbGbCtD
Methylnaltrexone—OPRM1—Amitriptyline—migraine	0.299	0.332	CbGbCtD
Methylnaltrexone—CYP2D6—Timolol—migraine	0.0804	0.0892	CbGbCtD
Methylnaltrexone—CYP2D6—Propranolol—migraine	0.0717	0.0795	CbGbCtD
Methylnaltrexone—CYP2D6—Amitriptyline—migraine	0.062	0.0688	CbGbCtD
Methylnaltrexone—CYP2D6—Verapamil—migraine	0.0492	0.0546	CbGbCtD
Methylnaltrexone—Stinging—Timolol—migraine	0.00261	0.0369	CcSEcCtD
Methylnaltrexone—Redness—Topiramate—migraine	0.00245	0.0347	CcSEcCtD
Methylnaltrexone—Injection site reaction—Valproic Acid—migraine	0.00236	0.0334	CcSEcCtD
Methylnaltrexone—Oedema—Amitriptyline—migraine	0.00159	0.0225	CcSEcCtD
Methylnaltrexone—Erythema—Propranolol—migraine	0.00159	0.0225	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Amitriptyline—migraine	0.00154	0.0218	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Propranolol—migraine	0.00134	0.019	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Propranolol—migraine	0.00127	0.018	CcSEcCtD
Methylnaltrexone—Skin disorder—Propranolol—migraine	0.00126	0.0178	CcSEcCtD
Methylnaltrexone—OPRM1—IL4-mediated signaling events—LTA—migraine	0.00122	0.0464	CbGpPWpGaD
Methylnaltrexone—Oedema—Verapamil—migraine	0.00119	0.0169	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Verapamil—migraine	0.00115	0.0163	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Propranolol—migraine	0.00112	0.0158	CcSEcCtD
Methylnaltrexone—Pain—Propranolol—migraine	0.00111	0.0157	CcSEcCtD
Methylnaltrexone—Diarrhoea—Amitriptyline—migraine	0.00109	0.0154	CcSEcCtD
Methylnaltrexone—Naloxone—ESR1—migraine	0.00107	1	CrCbGaD
Methylnaltrexone—Gastrointestinal pain—Propranolol—migraine	0.00106	0.015	CcSEcCtD
Methylnaltrexone—Dizziness—Amitriptyline—migraine	0.00105	0.0149	CcSEcCtD
Methylnaltrexone—Abdominal pain—Propranolol—migraine	0.00103	0.0145	CcSEcCtD
Methylnaltrexone—Flatulence—Valproic Acid—migraine	0.00102	0.0145	CcSEcCtD
Methylnaltrexone—Pain—Verapamil—migraine	0.00102	0.0144	CcSEcCtD
Methylnaltrexone—Vomiting—Amitriptyline—migraine	0.00101	0.0143	CcSEcCtD
Methylnaltrexone—Nausea—Amitriptyline—migraine	0.000947	0.0134	CcSEcCtD
Methylnaltrexone—Erythema—Timolol—migraine	0.000923	0.0131	CcSEcCtD
Methylnaltrexone—Diarrhoea—Propranolol—migraine	0.000888	0.0126	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—migraine	0.000877	0.0124	CcSEcCtD
Methylnaltrexone—Erythema—Gabapentin—migraine	0.00086	0.0122	CcSEcCtD
Methylnaltrexone—Dizziness—Propranolol—migraine	0.000858	0.0121	CcSEcCtD
Methylnaltrexone—Flatulence—Gabapentin—migraine	0.000847	0.012	CcSEcCtD
Methylnaltrexone—Oedema—Valproic Acid—migraine	0.000846	0.012	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Valproic Acid—migraine	0.00083	0.0117	CcSEcCtD
Methylnaltrexone—Vomiting—Propranolol—migraine	0.000825	0.0117	CcSEcCtD
Methylnaltrexone—Skin disorder—Valproic Acid—migraine	0.000822	0.0116	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Valproic Acid—migraine	0.000818	0.0116	CcSEcCtD
Methylnaltrexone—Diarrhoea—Verapamil—migraine	0.000817	0.0116	CcSEcCtD
Methylnaltrexone—Dizziness—Verapamil—migraine	0.000789	0.0112	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Timolol—migraine	0.000781	0.011	CcSEcCtD
Methylnaltrexone—Nausea—Propranolol—migraine	0.000771	0.0109	CcSEcCtD
Methylnaltrexone—Vomiting—Verapamil—migraine	0.000759	0.0107	CcSEcCtD
Methylnaltrexone—Oedema—Timolol—migraine	0.000754	0.0107	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Timolol—migraine	0.000739	0.0105	CcSEcCtD
Methylnaltrexone—Skin disorder—Timolol—migraine	0.000732	0.0104	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Valproic Acid—migraine	0.000731	0.0103	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Timolol—migraine	0.000728	0.0103	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—migraine	0.000727	0.0103	CcSEcCtD
Methylnaltrexone—Pain—Valproic Acid—migraine	0.000724	0.0102	CcSEcCtD
Methylnaltrexone—Erythema—Topiramate—migraine	0.000723	0.0102	CcSEcCtD
Methylnaltrexone—Flatulence—Topiramate—migraine	0.000713	0.0101	CcSEcCtD
Methylnaltrexone—Nausea—Verapamil—migraine	0.000709	0.01	CcSEcCtD
Methylnaltrexone—Oedema—Gabapentin—migraine	0.000702	0.00992	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Valproic Acid—migraine	0.000692	0.00979	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Gabapentin—migraine	0.000688	0.00973	CcSEcCtD
Methylnaltrexone—Skin disorder—Gabapentin—migraine	0.000682	0.00964	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Gabapentin—migraine	0.000678	0.00959	CcSEcCtD
Methylnaltrexone—Abdominal pain—Valproic Acid—migraine	0.000669	0.00946	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Timolol—migraine	0.000651	0.0092	CcSEcCtD
Methylnaltrexone—OPRK1—Mecp2 and Associated Rett Syndrome—BDNF—migraine	0.000648	0.0246	CbGpPWpGaD
Methylnaltrexone—Pain—Timolol—migraine	0.000644	0.00911	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Timolol—migraine	0.000616	0.00871	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide GPCRs—EDNRA—migraine	0.000614	0.0233	CbGpPWpGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Topiramate—migraine	0.000612	0.00865	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Gabapentin—migraine	0.000606	0.00857	CcSEcCtD
Methylnaltrexone—Pain—Gabapentin—migraine	0.0006	0.00849	CcSEcCtD
Methylnaltrexone—Abdominal pain—Timolol—migraine	0.000596	0.00842	CcSEcCtD
Methylnaltrexone—Oedema—Topiramate—migraine	0.00059	0.00835	CcSEcCtD
Methylnaltrexone—Diarrhoea—Valproic Acid—migraine	0.000579	0.00819	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Topiramate—migraine	0.000579	0.00819	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Gabapentin—migraine	0.000574	0.00811	CcSEcCtD
Methylnaltrexone—Skin disorder—Topiramate—migraine	0.000573	0.00811	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Topiramate—migraine	0.000571	0.00807	CcSEcCtD
Methylnaltrexone—Dizziness—Valproic Acid—migraine	0.00056	0.00792	CcSEcCtD
Methylnaltrexone—Abdominal pain—Gabapentin—migraine	0.000555	0.00784	CcSEcCtD
Methylnaltrexone—Vomiting—Valproic Acid—migraine	0.000538	0.00761	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide GPCRs—EDNRA—migraine	0.000519	0.0197	CbGpPWpGaD
Methylnaltrexone—Diarrhoea—Timolol—migraine	0.000516	0.00729	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Topiramate—migraine	0.00051	0.00721	CcSEcCtD
Methylnaltrexone—Pain—Topiramate—migraine	0.000505	0.00714	CcSEcCtD
Methylnaltrexone—Nausea—Valproic Acid—migraine	0.000503	0.00711	CcSEcCtD
Methylnaltrexone—Dizziness—Timolol—migraine	0.000498	0.00705	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Topiramate—migraine	0.000483	0.00683	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gabapentin—migraine	0.00048	0.00679	CcSEcCtD
Methylnaltrexone—Vomiting—Timolol—migraine	0.000479	0.00678	CcSEcCtD
Methylnaltrexone—Abdominal pain—Topiramate—migraine	0.000467	0.0066	CcSEcCtD
Methylnaltrexone—Dizziness—Gabapentin—migraine	0.000464	0.00656	CcSEcCtD
Methylnaltrexone—Nausea—Timolol—migraine	0.000448	0.00633	CcSEcCtD
Methylnaltrexone—Vomiting—Gabapentin—migraine	0.000446	0.00631	CcSEcCtD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—HTR1D—migraine	0.000445	0.0169	CbGpPWpGaD
Methylnaltrexone—Nausea—Gabapentin—migraine	0.000417	0.00589	CcSEcCtD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR1D—migraine	0.000413	0.0156	CbGpPWpGaD
Methylnaltrexone—Diarrhoea—Topiramate—migraine	0.000404	0.00571	CcSEcCtD
Methylnaltrexone—Dizziness—Topiramate—migraine	0.00039	0.00552	CcSEcCtD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2B—migraine	0.000384	0.0145	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—HTR1D—migraine	0.000376	0.0142	CbGpPWpGaD
Methylnaltrexone—Vomiting—Topiramate—migraine	0.000375	0.00531	CcSEcCtD
Methylnaltrexone—OPRK1—GPCR ligand binding—RAMP1—migraine	0.000371	0.014	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CALCRL—migraine	0.000371	0.014	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1D—migraine	0.000354	0.0134	CbGpPWpGaD
Methylnaltrexone—Nausea—Topiramate—migraine	0.000351	0.00496	CcSEcCtD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1D—migraine	0.000349	0.0132	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2B—migraine	0.000329	0.0125	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2B—migraine	0.000324	0.0123	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—RAMP1—migraine	0.000313	0.0119	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CALCRL—migraine	0.000313	0.0119	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—NPS—migraine	0.000303	0.0115	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—TAC1—migraine	0.000303	0.0115	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1D—migraine	0.000299	0.0113	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—EDNRA—migraine	0.000289	0.011	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2B—migraine	0.000278	0.0105	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—HTR1B—migraine	0.00027	0.0102	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR1D—migraine	0.000269	0.0102	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—HTR1A—migraine	0.000259	0.00983	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—TAC1—migraine	0.000256	0.0097	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—NPS—migraine	0.000256	0.0097	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR2B—migraine	0.00025	0.00949	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR1B—migraine	0.00025	0.00948	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—EDNRA—migraine	0.000244	0.00925	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR1A—migraine	0.000241	0.00912	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2C—migraine	0.000233	0.00881	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—HTR1B—migraine	0.000228	0.00863	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR1D—migraine	0.000228	0.00863	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—EDNRA—migraine	0.000226	0.00857	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—FOS—migraine	0.000224	0.00849	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—HTR1A—migraine	0.000219	0.00831	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1B—migraine	0.000214	0.00812	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR2B—migraine	0.000212	0.00802	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1B—migraine	0.000211	0.00801	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—RAMP1—migraine	0.00021	0.00794	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CALCRL—migraine	0.00021	0.00794	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR1A—migraine	0.000206	0.00782	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR7—migraine	0.000204	0.00772	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR1A—migraine	0.000204	0.00771	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—NPS—migraine	0.000203	0.0077	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—TAC1—migraine	0.000203	0.0077	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2C—migraine	0.000199	0.00755	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2C—migraine	0.000197	0.00745	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—EDNRA—migraine	0.000194	0.00734	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—EDNRA—migraine	0.000191	0.00725	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—RAMP1—migraine	0.00019	0.00721	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CALCRL—migraine	0.00019	0.00721	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—migraine	0.000181	0.00686	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—RAMP1—migraine	0.000177	0.00671	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CALCRL—migraine	0.000177	0.00671	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR7—migraine	0.000175	0.00661	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR1A—migraine	0.000174	0.00661	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR7—migraine	0.000172	0.00652	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—TAC1—migraine	0.000172	0.00651	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—NPS—migraine	0.000172	0.00651	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2C—migraine	0.000168	0.00638	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDNRA—migraine	0.000164	0.00621	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR1B—migraine	0.000163	0.00618	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CALCRL—migraine	0.000161	0.00609	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—RAMP1—migraine	0.000161	0.00609	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR1A—migraine	0.000157	0.00595	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—NPS—migraine	0.000155	0.00586	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—TAC1—migraine	0.000155	0.00586	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR1D—migraine	0.000152	0.00577	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR2C—migraine	0.000152	0.00575	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—EDNRA—migraine	0.000148	0.00559	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR7—migraine	0.000147	0.00559	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—migraine	0.000143	0.00541	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CALCA—migraine	0.000142	0.00538	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR2B—migraine	0.000142	0.00536	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR1D—migraine	0.000138	0.00524	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR1B—migraine	0.000138	0.00523	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR7—migraine	0.000133	0.00504	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR1A—migraine	0.000133	0.00503	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—NPS—migraine	0.000131	0.00496	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—TAC1—migraine	0.000131	0.00496	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR1D—migraine	0.000129	0.00488	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR2B—migraine	0.000129	0.00487	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR2C—migraine	0.000128	0.00486	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—EDNRA—migraine	0.000125	0.00473	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—migraine	0.000122	0.00463	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—migraine	0.000121	0.00457	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CALCA—migraine	0.00012	0.00455	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR2B—migraine	0.00012	0.00453	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR1D—migraine	0.000117	0.00443	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RAMP1—migraine	0.000112	0.00426	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CALCRL—migraine	0.000112	0.00426	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR7—migraine	0.000112	0.00426	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR2B—migraine	0.000109	0.00412	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—migraine	0.000103	0.00391	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RAMP1—migraine	9.5e-05	0.0036	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CALCRL—migraine	9.5e-05	0.0036	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—HTR2A—migraine	9.31e-05	0.00353	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR1B—migraine	9.22e-05	0.0035	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR1A—migraine	8.88e-05	0.00336	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—NPS—migraine	8.74e-05	0.00331	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—TAC1—migraine	8.74e-05	0.00331	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR2C—migraine	8.57e-05	0.00325	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR1B—migraine	8.38e-05	0.00317	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—EDNRA—migraine	8.34e-05	0.00316	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR1D—migraine	8.17e-05	0.00309	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR1A—migraine	8.06e-05	0.00306	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CALCA—migraine	8.03e-05	0.00304	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—TAC1—migraine	7.94e-05	0.00301	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—NPS—migraine	7.94e-05	0.00301	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—HTR2A—migraine	7.87e-05	0.00298	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR1B—migraine	7.8e-05	0.00295	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR2C—migraine	7.79e-05	0.00295	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2B—migraine	7.59e-05	0.00288	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EDNRA—migraine	7.57e-05	0.00287	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR7—migraine	7.51e-05	0.00285	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR1A—migraine	7.5e-05	0.00284	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—NPS—migraine	7.39e-05	0.0028	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—TAC1—migraine	7.39e-05	0.0028	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CALCA—migraine	7.29e-05	0.00276	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR2C—migraine	7.25e-05	0.00275	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR1B—migraine	7.08e-05	0.00268	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—EDNRA—migraine	7.05e-05	0.00267	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR1D—migraine	6.9e-05	0.00262	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR7—migraine	6.82e-05	0.00258	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR1A—migraine	6.81e-05	0.00258	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CALCA—migraine	6.79e-05	0.00257	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—NPS—migraine	6.71e-05	0.00254	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—TAC1—migraine	6.71e-05	0.00254	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LRP1—migraine	6.68e-05	0.00253	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR2C—migraine	6.58e-05	0.00249	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2B—migraine	6.42e-05	0.00243	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EDNRA—migraine	6.4e-05	0.00243	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR7—migraine	6.35e-05	0.00241	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CALCA—migraine	6.16e-05	0.00234	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR7—migraine	5.76e-05	0.00218	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LRP1—migraine	5.65e-05	0.00214	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—HTR2A—migraine	5.26e-05	0.00199	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH4—migraine	5.13e-05	0.00194	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR1B—migraine	4.95e-05	0.00187	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HTR2A—migraine	4.78e-05	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR1A—migraine	4.76e-05	0.0018	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TAC1—migraine	4.69e-05	0.00178	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PGR—migraine	4.69e-05	0.00178	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NPS—migraine	4.69e-05	0.00178	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2C—migraine	4.6e-05	0.00174	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDNRA—migraine	4.47e-05	0.0017	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—HTR2A—migraine	4.45e-05	0.00168	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH3—migraine	4.36e-05	0.00165	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH4—migraine	4.33e-05	0.00164	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CALCA—migraine	4.31e-05	0.00163	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR1B—migraine	4.18e-05	0.00158	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR2A—migraine	4.04e-05	0.00153	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR7—migraine	4.03e-05	0.00153	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR1A—migraine	4.03e-05	0.00153	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PGR—migraine	3.96e-05	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TAC1—migraine	3.96e-05	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NPS—migraine	3.96e-05	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2C—migraine	3.89e-05	0.00147	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CACNA1A—migraine	3.81e-05	0.00144	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDNRA—migraine	3.78e-05	0.00143	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH3—migraine	3.69e-05	0.0014	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CALCA—migraine	3.64e-05	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFBR2—migraine	3.47e-05	0.00131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR7—migraine	3.4e-05	0.00129	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFBR2—migraine	2.93e-05	0.00111	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2A—migraine	2.82e-05	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ESR1—migraine	2.5e-05	0.000949	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2A—migraine	2.38e-05	0.000904	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ESR1—migraine	2.12e-05	0.000802	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—migraine	1.26e-05	0.000477	CbGpPWpGaD
